Skip to main content
SpringerLink
Log in

Epithelial Mesenchymal Transition in Aggressive Lung Cancers

  • Chapter
  • First Online:
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 890))

Abstract

The progression of a cancer cell into a metastatic entity contributes to more than 90 % of cancer related deaths. Therefore, the prevention and treatment of metastasis is an unmet clinical need. Epithelial to mesenchymal transition (EMT) is an evolutionary conserved developmental program, which is induced during cancer progression and contributes to metastatic colonization. EMT endows metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit therapeutic resistance. The disseminated tumor cells recruited to distant organs are suggested to subsequently undergo an EMT reversion through mesenchymal to epithelial transition (MET), necessary for efficient colonization and macrometastasis. A major focus of cancer research is to determine the cellular and molecular mechanisms underlying EMT/MET in tumor invasion, dissemination and metastasis. In this chapter, we will focus on the contribution of the EMT signaling pathways in lung cancer progression, cancer stem cells and acquired resistance to EGFR tyrosine kinase inhibitors and chemotherapy. We will also discuss the potential of targeting EMT pathways as an attractive strategy for the treatment of lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lim J, Thiery JP (2012) Epithelial-mesenchymal transitions: insights from development. Development 139:3471–3486

    Article  PubMed  CAS  Google Scholar 

  2. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW (2007) Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 213:374–383

    Article  PubMed  CAS  Google Scholar 

  3. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890

    Article  PubMed  CAS  Google Scholar 

  4. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818–829

    Article  PubMed  CAS  Google Scholar 

  5. Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15:178–196

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Said NA, Williams ED (2011) Growth factors in induction of epithelial-mesenchymal transition and metastasis. Cells Tissues Organs 193:85–97

    Article  PubMed  CAS  Google Scholar 

  7. De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97–110

    Article  PubMed  CAS  Google Scholar 

  8. Nieto MA (2011) The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 27:347–376

    Article  PubMed  CAS  Google Scholar 

  9. Tam WL, Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19:1438–1449

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD (2011) A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 28:137–155

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Dave B, Mittal V, Tan NM, Chang JC (2012) Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14:202

    Article  PubMed  PubMed Central  Google Scholar 

  12. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3, e2888

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI et al (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106:13820–13825

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Ocaña OH, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA (2012) Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22:709–724

    Article  PubMed  CAS  Google Scholar 

  16. Gao D, Mittal V (2012) Tumor microenvironment regulates epithelial-mesenchymal transitions in metastasis. Expert Rev Anticancer Ther 12:857–859

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Gao D, Vahdat LT, Wong S, Chang JC, Mittal V (2012) Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res 72:4883–4889

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Katoh Y, Katoh M (2008) Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med 22:271–275

    PubMed  CAS  Google Scholar 

  19. Moustakas A, Heldin CH (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98:1512–1520

    Article  PubMed  CAS  Google Scholar 

  20. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL et al (2011) Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145:926–940

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT et al (2012) Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res 72:1384–1394

    Article  PubMed  CAS  Google Scholar 

  22. Sheng W, Wang G, La Pierre DP, Wen J, Deng Z, Wong CK, Lee DY, Yang BB (2006) Versican mediates mesenchymal-epithelial transition. Mol Biol Cell 17:2009–2020

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Bastid J (2012) EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev 31:277–283

    Article  PubMed  Google Scholar 

  24. Brabletz T (2012) To differentiate or not–routes towards metastasis. Nat Rev Cancer 12:425–436

    Article  PubMed  CAS  Google Scholar 

  25. Ledford H (2011) Cancer theory faces doubts. Nature 472:273

    Article  PubMed  CAS  Google Scholar 

  26. Tarin D, Thompson EW, Newgreen DF (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65:5996–6000, discussion 6000–5991

    Article  PubMed  CAS  Google Scholar 

  27. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420–1428

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Zeisberg M, Kalluri R (2013) Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol 304:C216–C225

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Chaffer CL, Thompson EW, Williams ED (2007) Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185:7–19

    Article  PubMed  Google Scholar 

  30. Jeschke U, Mylonas I, Kuhn C, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K (2007) Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence. Anticancer Res 27:1969–1974

    PubMed  CAS  Google Scholar 

  31. Park D, Kåresen R, Axcrona U, Noren T, Sauer T (2007) Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis. APMIS 115:52–65

    Article  PubMed  CAS  Google Scholar 

  32. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y et al (2011) Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17:1101–1108

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Scheel C, Weinberg RA (2011) Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer 129:2310–2314

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116–4124

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273

    Article  PubMed  CAS  Google Scholar 

  36. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E (2009) Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 11:1287–1296

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Xue C, Plieth D, Venkov C, Xu C, Neilson EG (2003) The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63:3386–3394

    PubMed  CAS  Google Scholar 

  38. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J (2012) Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22:725–736

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH et al (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148:349–361

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Trimboli AJ, Fukino K, de Bruin A, Wei G, Shen L, Tanner SM, Creasap N, Rosol TJ, Robinson ML, Eng C et al (2008) Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68:937–945

    Article  PubMed  CAS  Google Scholar 

  41. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29

    Article  PubMed  Google Scholar 

  42. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734–1739

    Article  PubMed  CAS  Google Scholar 

  43. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043

    Article  PubMed  CAS  Google Scholar 

  44. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Xiao D, He J (2010) Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2:154–159

    PubMed  PubMed Central  CAS  Google Scholar 

  46. Jiang W, Pang XG, Wang Q, Shen YX, Chen XK, Xi JJ (2012) Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection. Clin Lung Cancer 13:280–287

    Article  PubMed  CAS  Google Scholar 

  47. Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II (2009) Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol 22:668–678

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M, Guo YH, Shi J, Gong XD, Zhu YL, Liu F et al (2014) Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer. Oncol Rep 31:2660–2668

    PubMed  CAS  Google Scholar 

  49. Soltermann A (2012) Epithelial-mesenchymal transition in non-small cell lung cancer. Pathologe 33(suppl 2):311–317

    Article  PubMed  Google Scholar 

  50. Morra L, Moch H (2011) Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch 459:465–475

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G (2008) Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 14:7430–7437

    Article  PubMed  CAS  Google Scholar 

  52. Reka AK, Chen G, Jones RC, Amunugama R, Kim S, Karnovsky A, Standiford TJ, Beer DG, Omenn GS, Keshamouni VG (2014) Epithelial-mesenchymal transition-associated secretory phenotype predicts survival in lung cancer patients. Carcinogenesis 35:1292–1300

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Tian Y, Lu M, Yue W, Li L, Li S, Gao C, Si L, Qi L, Hu W, Tian H (2014) TFIIB-related factor 2 is associated with poor prognosis of nonsmall cell lung cancer patients through promoting tumor epithelial-mesenchymal transition. Biomed Res Int 2014:530786

    PubMed  PubMed Central  Google Scholar 

  54. Sun M, Liu XH, Wang KM, Nie FQ, Kong R, Yang JS, Xia R, Xu TP, Jin FY, Liu ZJ et al (2014) Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Mol Cancer 13:68

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu Z, Zhao J, Zhang HT (2014) JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol 44:1643–1651

    PubMed  CAS  Google Scholar 

  56. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, Keshamouni VG (2010) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 9:3221–3232

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, Martucci N, Paino F, Normanno N, Rocco G (2011) Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One 6, e21548

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Pirozzi G, Tirino V, Camerlingo R, La Rocca A, Martucci N, Scognamiglio G, Franco R, Cantile M, Normanno N, Rocco G (2013) Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. Oncol Rep 29:1763–1768

    PubMed  CAS  Google Scholar 

  59. Tirino V, Camerlingo R, Bifulco K, Irollo E, Montella R, Paino F, Sessa G, Carriero MV, Normanno N, Rocco G et al (2013) TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell Death Dis 4, e620

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH et al (2013) Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition. Cancer Res 73:7111–7121

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Liu CW, Li CH, Peng YJ, Cheng YW, Chen HW, Liao PL, Kang JJ, Yeng MH (2014) Snail regulates Nanog status during the epithelial-mesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer. Oncotarget 5:3880–3894

    Article  PubMed  PubMed Central  Google Scholar 

  62. Westhoff B, Colaluca IN, D’Ario G, Donzelli M, Tosoni D, Volorio S, Pelosi G, Spaggiari L, Mazzarol G, Viale G et al (2009) Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A 106:22293–22298

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Xu K, Moghal N, Egan SE (2012) Notch signaling in lung development and disease. Adv Exp Med Biol 727:89–98

    Article  PubMed  CAS  Google Scholar 

  64. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 105:6392–6397

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Zavadil J, Cermak L, Soto-Nieves N, Böttinger EP (2004) Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 23:1155–1165

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Kang J, Kim E, Kim W, Seong KM, Youn H, Kim JW, Kim J, Youn B (2013) Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem 288:27343–27357

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Ji X, Wang Z, Geamanu A, Goja A, Sarkar FH, Gupta SV (2012) Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int J Cancer 131:2668–2677

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  68. Baumgart A, Mazur PK, Anton M, Rudelius M, Schwamborn K, Feuchtinger A, Behnke K, Walch A, Braren R, Peschel C et al (2015) Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model. Oncogene 34:578–588

    Article  PubMed  CAS  Google Scholar 

  69. Mimae T, Okada M, Hagiyama M, Miyata Y, Tsutani Y, Inoue T, Murakami Y, Ito A (2012) Upregulation of notch2 and six1 is associated with progression of early-stage lung adenocarcinoma and a more aggressive phenotype at advanced stages. Clin Cancer Res 18:945–955

    Article  PubMed  CAS  Google Scholar 

  70. You J, Li Y, Fang N, Liu B, Zu L, Chang R, Li X, Zhou Q (2014) MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2. PLoS One 9, e91827

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Ke Y, Zhao W, Xiong J, Cao R (2013) miR-149 inhibits non-small-cell lung cancer cells EMT by targeting FOXM1. Biochem Res Int 2013:506731

    Google Scholar 

  72. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T (2008) A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9:582–589

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601

    Article  PubMed  CAS  Google Scholar 

  74. Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283:14910–14914

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22:894–907

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  76. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A et al (2009) Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23:2140–2151

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, Allgayer H (2010) Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8:1207–1216

    Article  PubMed  CAS  Google Scholar 

  78. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S, Belinsky SA (2011) EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 71:3087–3097

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4:e7181

    Google Scholar 

  80. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D (2009) MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 23:2152–2165

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Boldrini L, Donati V, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F et al (2005) Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93:453–457

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Donati V, Boldrini L, Dell’Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F et al (2005) Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11:6459–6465

    Article  PubMed  CAS  Google Scholar 

  83. Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, Kao ST, Tsai FJ, Chen WC, Chen CY, Tang CH (2009) Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64:263–270

    Article  PubMed  Google Scholar 

  84. Shah PP, Fong MY, Kakar SS (2012) PTTG induces EMT through integrin αVβ3-focal adhesion kinase signaling in lung cancer cells. Oncogene 31:3124–3135

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Mise N, Savai R, Yu H, Schwarz J, Kaminski N, Eickelberg O (2012) Zyxin is a transforming growth factor-β (TGF-β)/Smad3 target gene that regulates lung cancer cell motility via integrin α5β1. J Biol Chem 287:31393–31405

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Heinrich EL, Walser TC, Krysan K, Liclican EL, Grant JL, Rodriguez NL, Dubinett SM (2012) The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenviron 5:5–18

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM (2008) Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol 3:107–110

    Google Scholar 

  88. Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, Wang G, Walser TC, Krysan K, Sharma S et al (2013) IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res 32:97

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC et al (2006) Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 66:5338–5345

    Article  PubMed  CAS  Google Scholar 

  90. Nagathihalli NS, Massion PP, Gonzalez AL, Lu P, Datta PK (2012) Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. Mol Cancer Ther 11:2362–2372

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Shen HJ, Sun YH, Zhang SJ, Jiang JX, Dong XW, Jia YL, Shen J, Guan Y, Zhang LH, Li FF et al (2014) Cigarette smoke-induced alveolar epithelial-mesenchymal transition is mediated by Rac1 activation. Biochim Biophys Acta 1840:1838–1849

    Article  PubMed  CAS  Google Scholar 

  92. Illman SA, Lehti K, Keski-Oja J, Lohi J (2006) Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 119:3856–3865

    Article  PubMed  CAS  Google Scholar 

  93. McGuire JK, Li Q, Parks WC (2003) Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162:1831–1843

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Radisky DC, Przybylo JA (2008) Matrix metalloproteinase-induced fibrosis and malignancy in breast and lung. Proc Am Thorac Soc 5:316–322

    Article  PubMed  CAS  Google Scholar 

  95. Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC (2012) Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med 4:142ra195

    Article  CAS  Google Scholar 

  96. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G et al (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18:74–82

    CAS  Google Scholar 

  97. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD (2008) Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25:843–854

    Article  PubMed  CAS  Google Scholar 

  98. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S et al (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11:8686–8698

    Article  PubMed  CAS  Google Scholar 

  99. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ (2007) Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 6:277–285

    Article  PubMed  CAS  Google Scholar 

  100. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Raben D (2007) Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6:1683–1691

    Article  PubMed  CAS  Google Scholar 

  101. Yin T, Wang C, Liu T, Zhao G, Zha Y, Yang M (2007) Expression of snail in pancreatic cancer promotes metastasis and chemoresistance. J Surg Res 141:196–203

    Article  PubMed  CAS  Google Scholar 

  102. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679

    Article  PubMed  CAS  Google Scholar 

  103. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932–20937

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA et al (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69–80

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Voulgari A, Pintzas A (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796:75–90

    PubMed  CAS  Google Scholar 

  106. La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R et al (2013) Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One 8, e78656

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  107. Buonato JM, Lazzara MJ (2014) ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res 74:309–319

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. Yoon YK, Kim HP, Han SW, Hur HS, Oh DY, Im SA, Bang YJ, Kim TY (2009) Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 8:2526–2536

    Article  PubMed  CAS  Google Scholar 

  109. Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H (2011) Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res 17:2744–2756

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V et al (2010) TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 107:15535–15540

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B et al (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117:3846–3856

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  112. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20:1496–1510

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, Li K, Chen H, Sun F, Yang Z et al (2014) Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res 20:2714–2726

    Article  PubMed  CAS  Google Scholar 

  114. Ning J, Liu W, Zhang J, Lang Y, Xu S (2014) Ran GTPase induces EMT and enhances invasion in non-small cell lung cancer cells through activation of PI3K-AKT pathway. Oncol Res 21:67–72

    Article  CAS  Google Scholar 

  115. Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, Zhao LP, Tian Y (2012) Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem 113:1501–1513

    PubMed  CAS  Google Scholar 

  116. Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J et al (2013) Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res 73:406–416

    Article  PubMed  CAS  Google Scholar 

  117. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, Kalemkerian GP, Wicha MS (2013) Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 19:1972–1980

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Theys J, Yahyanejad S, Habets R, Span P, Dubois L, Paesmans K, Kattenbeld B, Cleutjens J, Groot AJ, Schuurbiers OC et al (2013) High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiother Oncol 108:440–445

    Article  PubMed  CAS  Google Scholar 

  119. Yue D, Li H, Che J, Zhang Y, Tseng HH, Jin JQ, Luh TM, Giroux-Leprieur E, Mo M, Zheng Q et al (2014) Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J Exp Clin Cancer Res 33:34

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  120. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH (2011) Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One 6, e16068

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  121. Ahmad A, Maitah MY, Ginnebaugh KR, Li Y, Bao B, Gadgeel SM, Sarkar FH (2013) Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol 6:77

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  122. Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A (2014) MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 13:444–453

    Article  PubMed  CAS  Google Scholar 

  123. Thatcher N, Faivre-Finn C, Blackhall F, Anderson H, Lorigan P (2005) Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer. Clin Cancer Res 11:5051s–5056s

    Google Scholar 

  124. Socinski MA (2004) Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy. Clin Lung Cancer 5:274–289

    Article  PubMed  CAS  Google Scholar 

  125. Yu M, Zhang C, Li L, Dong S, Zhang N, Tong X (2014) Cx43 reverses the resistance of A549 lung adenocarcinoma cells to cisplatin by inhibiting EMT. Oncol Rep 31:2751–2758

    PubMed  CAS  Google Scholar 

  126. Ren J, Chen Y, Song H, Chen L, Wang R (2013) Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem 114:1395–1403

    Article  PubMed  CAS  Google Scholar 

  127. Ju L, Zhou C (2013) Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer. Cancer Biomark 13:329–336

    PubMed  CAS  Google Scholar 

  128. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741–4751

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  129. Ginnebaugh KR, Ahmad A, Sarkar FH (2014) The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer. Expert Opin Ther Targets 18:731–745

    Article  PubMed  CAS  Google Scholar 

  130. Niederst MJ, Engelman JA (2013) Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 6:re6

    Google Scholar 

  131. Cañadas I, Rojo F, Taus Á, Arpí O, Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M et al (2014) Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res 20:938–950

    Article  PubMed  CAS  Google Scholar 

  132. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AM, Yang JC (2013) MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol 7:112–120

    Article  PubMed  CAS  Google Scholar 

  133. Zhao Z, Cheng X, Wang Y, Han R, Li L, Xiang T, He L, Long H, Zhu B, He Y (2014) Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS One 9, e95884

    Article  PubMed  PubMed Central  Google Scholar 

  134. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK et al (2013) An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19:279–290

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  135. Iida S, Miki Y, Suzuki T, Mori K, Saito M, Niikawa H, Kondo T, Yamada-Okabe H, Sasano H (2014) Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma. Anticancer Res 34:1821–1827

    PubMed  CAS  Google Scholar 

  136. Niederst MJ, Benes CH (2014) EMT twists the road to PI3K. Cancer Discov 4:149–151

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  137. Salt MB, Bandyopadhyay S, McCormick F (2014) Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov 4:186–199

    Article  PubMed  CAS  Google Scholar 

  138. Wald O, Shapira OM, Izhar U (2013) CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics 3:26–33

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  139. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S et al (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106:16281–16286

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  140. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG, Lee JS, Lee SJ, Lee JC, Park MJ (2013) Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 32:209–221

    Article  PubMed  CAS  Google Scholar 

  141. Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, DiJoseph JF, Karnoub M, Huang S, Diesl V et al (2011) Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 71:4236–4246

    Article  PubMed  CAS  Google Scholar 

  142. Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, Shapira OM et al (2012) In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J Thorac Cardiovasc Surg 144:1167–1175.e1161

    Google Scholar 

  143. Otani Y, Kijima T, Kohmo S, Oishi S, Minami T, Nagatomo I, Takahashi R, Hirata H, Suzuki M, Inoue K et al (2012) Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016. FEBS Lett 586:3639–3644

    Article  PubMed  CAS  Google Scholar 

  144. Peled A, Wald O, Burger J (2012) Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 21:341–353

    Article  PubMed  CAS  Google Scholar 

  145. Wang H, Zhang G, Zhang H, Zhang F, Zhou B, Ning F, Wang HS, Cai SH, Du J (2014) Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway. Eur J Pharmacol 723:156–166

    Article  PubMed  CAS  Google Scholar 

  146. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M et al (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66:944–950

    Article  PubMed  CAS  Google Scholar 

  147. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852–860

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  148. Nagaraj NS, Datta PK (2010) Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 19:77–91

    Article  PubMed  CAS  Google Scholar 

  149. Park CY, Min KN, Son JY, Park SY, Nam JS, Kim DK, Sheen YY (2014) An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition. Cancer Lett 351:72–80

    Article  PubMed  CAS  Google Scholar 

  150. Stewart DJ (2014) Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 106:djt356

    Article  PubMed  CAS  Google Scholar 

  151. Stewart DJ, Chang DW, Ye Y, Spitz M, Lu C, Shu X, Wampfler JA, Marks RS, Garces YI, Yang P et al (2014) Wnt signaling pathway pharmacogenetics in non-small cell lung cancer. Pharmacogenomics J 14:509–522

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  152. Hofman V, Ilie MI, Long E, Selva E, Bonnetaud C, Molina T, Vénissac N, Mouroux J, Vielh P, Hofman P (2011) Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the Cell Search Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer 129:1651–1660

    Article  PubMed  CAS  Google Scholar 

  153. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F (2011) Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 105:1338–1341

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgments

We thank Sharrell Lee for reading the manuscript. VM is supported by NIH grants and by Cornell Center on the Microenvironment and Metastasis through Award Number U54CA143876 from the National Cancer Institute, and the Neuberger Berman Lung Cancer Center. The authors apologize for studies that could not be included due to space limitations.

Author information

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, Neuberger Berman Foundation Lung Cancer Center, New York, NY, 10065, USA

    Vivek Mittal

  2. Department of Cell and Developmental Biology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY, 10065, USA

    Vivek Mittal

Authors
  1. Vivek Mittal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vivek Mittal .

Editor information

Editors and Affiliations

  1. Wayne State University, Karmanos Cancer Institute, Detroit, Michigan, USA

    Aamir Ahmad

  2. Karamanos Cancer Institute, Wayne State University, Detroit, Michigan, USA

    Shirish M. Gadgeel

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mittal, V. (2016). Epithelial Mesenchymal Transition in Aggressive Lung Cancers. In: Ahmad, A., Gadgeel, S. (eds) Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Advances in Experimental Medicine and Biology, vol 890. Springer, Cham. https://doi.org/10.1007/978-3-319-24932-2_3

Download citation

Publish with us

Policies and ethics

Search

Navigation